1201 Orange Street
Suite 600
Wilmington, DE 19801
United States
(484) 254-6134
https://www.nrxpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Jonathan C. Javitt M.D., M.P.H. | Co-Founder, Chief Scientist Officer & Chairman | 630.2k | N/A | 1957 |
Mr. Stephen H. Willard Esq. | Acting Corporate Secretary, CEO & Director | 500k | N/A | 1961 |
Mr. Richard Clavano Narido | CFO & Treasurer | 255.01k | N/A | 1979 |
Dr. Riccardo Panicucci Ph.D. | Chief Manufacturing & Technology Officer | 240k | N/A | 1961 |
Suzanne Messere | Investor Relations | N/A | N/A | N/A |
Dr. Philip T. Lavin Ph.D. | Chief Methodologist | N/A | N/A | 1947 |
Mr. Matthew Patrick Duffy | Chief Business Officer | N/A | N/A | 1963 |
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
NRx Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.